Over-expression of β-catenin is associated with high grade of prostatic cancer in Libyan patients

Abstract

ObjectivesAt present, sufficient prognostic markers for prostate cancer (PCa) progression are still lacking, in spite of thorough investigation. The aim of this study was to evaluate abnormalities of β-catenin protein expression, subcellular localization and determine its relation to different clinicopathological features and disease free survival in prostate cancer patients. Patients and methodsForty prostate cancer specimens, obtained from patients with different stages of prostate cancer (83% stage IV) who underwent a radical prostatectomy or TURP flanked by 2006 and 2011, β-catenin was determined by immuno-histochemistry (IHC). The membranous expression was semi-quantitatively evaluated in four scores (0, 1+, 2+, 3+). Clinical records of these patients were studied for follow up data. Resultsβ-Catenin immune staining results show over-expression of β-catenin in PCa Libyan patients. There was no statistically significant difference in β-catenin immune expression as regards histopathological type, perineural invasion, tumor stage, biological recurrence. However, β-catenin over-expression showed significant correlation with old age (p<0.014). ConclusionsWe concluded that changes in expression and cell distribution of β-catenin correlated with the progression degree of prostate adenocarcinoma, signifying a role of this molecule as a marker of progression and prognosis. Further investigations, on a larger and more heterogeneous population, should be carried out to validate and extend our results.